This bill would require a federal study of payment deals in the prescription drug supply chain that rise or fall with a drug’s price. The study would look closely at Medicare Part D and Medicaid. It would not change drug prices or benefits right away.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Prescription Drug Supply Chain Pricing Transparency Act is a Senate bill in committee. The latest recorded action: Read twice and referred to the Committee on Finance.
Latest action on S. 3751: Read twice and referred to the Committee on Finance.
Who this affects: This bill mainly affects the businesses and programs involved in paying for and moving prescription drugs. It matters most to pharmacy benefit managers, Medicare Part D plans, pharmacies, wholesalers, drugmakers, and Medicaid because GAO would examine how they get paid and whether those payment setups create conflicts. Patients and health plans are affected more indirectly. The bill could shape later policy choices that change drug coverage, prices, or business rules.
Why this matters: This matters because people pay for prescription drugs through a complicated chain of companies, and some of those companies may make more money when drug prices are higher. This bill tries to show how those payment deals work in real life. It could help Congress understand whether certain fee structures affect which drugs get covered, bought, or stocked. The bill itself does not change prices or benefits, so any direct effect would come later if lawmakers or agencies act on the report.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
